BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 34305920)

  • 1. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
    Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
    Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
    Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
    Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.
    Mathewson ND; Ashenberg O; Tirosh I; Gritsch S; Perez EM; Marx S; Jerby-Arnon L; Chanoch-Myers R; Hara T; Richman AR; Ito Y; Pyrdol J; Friedrich M; Schumann K; Poitras MJ; Gokhale PC; Gonzalez Castro LN; Shore ME; Hebert CM; Shaw B; Cahill HL; Drummond M; Zhang W; Olawoyin O; Wakimoto H; Rozenblatt-Rosen O; Brastianos PK; Liu XS; Jones PS; Cahill DP; Frosch MP; Louis DN; Freeman GJ; Ligon KL; Marson A; Chiocca EA; Reardon DA; Regev A; Suvà ML; Wucherpfennig KW
    Cell; 2021 Mar; 184(5):1281-1298.e26. PubMed ID: 33592174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
    Qiu P; Guo Q; Yao Q; Chen J; Lin J
    Front Immunol; 2021; 12():736030. PubMed ID: 34659224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors.
    Cheng X; Cao Y; Wang X; Cheng L; Liu Y; Lei J; Peng W; Shi D
    J Immunol Res; 2022; 2022():5254911. PubMed ID: 35028320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer Analysis.
    Ye W; Luo C; Li C; Liu Z; Liu F
    J Cancer; 2021; 12(21):6588-6599. PubMed ID: 34659549
    [No Abstract]   [Full Text] [Related]  

  • 10. PNOC Expressed by B Cells in Cholangiocarcinoma Was Survival Related and LAIR2 Could Be a T Cell Exhaustion Biomarker in Tumor Microenvironment: Characterization of Immune Microenvironment Combining Single-Cell and Bulk Sequencing Technology.
    Chen Z; Yu M; Yan J; Guo L; Zhang B; Liu S; Lei J; Zhang W; Zhou B; Gao J; Yang Z; Li X; Zhou J; Fan J; Ye Q; Li H; Xu Y; Xiao Y
    Front Immunol; 2021; 12():647209. PubMed ID: 33841428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC.
    Oh MS; Anker JF; Chae YK
    Cancer Treat Res Commun; 2021; 27():100317. PubMed ID: 33711637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
    Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
    Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
    Xu HH; Gan J; Xu DP; Li L; Yan WH
    Front Immunol; 2021; 12():614773. PubMed ID: 34276642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of an immune-related gene signature for prediction of prognosis in patients with cervical cancer.
    Mei J; Xing Y; Lv J; Gu D; Pan J; Zhang Y; Liu J
    Int Immunopharmacol; 2020 Nov; 88():106882. PubMed ID: 32799114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma.
    Wang N; Zhou X; Tang F; Wang X; Zhu X
    Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMTM3 as a Potential New Immune Checkpoint Regulator.
    Shen Q; Cong Z; Zhou Y; Teng Y; Gao J; Tang W
    J Oncol; 2022; 2022():2103515. PubMed ID: 36245970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer.
    Liu B; Fu T; He P; Du C; Xu K
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34143198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
    Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
    Front Immunol; 2020; 11():558757. PubMed ID: 33329517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
    Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
    Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.